Trxc Stock Buy Or Sell ❲FAST ⚡❳

: On August 22, 2024, KARL STORZ finalized its acquisition of Asensus Surgical.

: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC)

: KARL STORZ acquired the company primarily for its Senhance Surgical System and the development of the next-generation LUNA™ System , aiming to integrate these into their global endoscopy portfolio. trxc stock buy or sell

: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook

: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout. : On August 22, 2024, KARL STORZ finalized

: In March 2021, the company changed its name from TransEnterix to Asensus Surgical to align with its focus on "Performance-Guided Surgery".

: The symbol transitioned from TRXC to ASXC as part of this corporate shift. : Leading up to its acquisition, the company

Since the company is now , it is not possible to buy or sell shares on public markets.